AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its ...

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D) ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca's strategic $50B investment promises to revolutionize U.S. medicine production with advanced manufacturing and ...

The money will focus on a manufacturing plant in Virginia that will make the company's weight management and metabolic drugs ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or ...